Claims
- 1. A method of treatment of anxiety disorders treatable with anti-convulsive agents which comprises administering to the sufferer in need thereof an effective amount of a compound wherein the compound is:
- trans-6-ethyl-3,4-dihydro-2,2-dimethyl-4S-(2-pyridinylcarbonyl)amino-2H-1-benzopyran-3R-ol,
- trans-6-cyano-4S-(5-chloro-2-thiophenylcarbonylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-4-(4-chlorobenzoylamino)-6-cyano-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-cyano-3,4-dihydro-2,2-dimethyl-4S-(4-nitrobenzoylamino)-2H-1-benzopyran-3R-ol,
- trans-4S-(4-aminobenzoylamino)-6-cyano-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-cyano-4-(4-trifluoromethyl-benzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Cyano-4-(2-iodobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4-(3-Bromo-4-fluorobenzoylamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4S-(3-Bromo-4-fluorobenzoylamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Ethyl-4-(3-trifluoro-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4-(4-Bromobenzoylamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4-(3-Fluoro-4-methylbenzoylamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4-(3-fluoro-4-methoxyamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4-(3-Chloro-4-fluorobenzoylamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4-(3-bromobenzoylamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-4-(4-Fluoro-3-methylbenzoylamino)-6-ethyl-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-bromo-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-bromobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-bromobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(5-bromo-2-furanoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-azidobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-azidobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-chlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-trifluoromethylbenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-benzoylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol
- trans-6-Acetyl-4-(2-iodobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-iodobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-nitrobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-chlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-cyanobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(4-chlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-aminobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-nitrobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-trifluoromethoxybenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4S-(2-chlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Acetyl-4-(2,3-dichlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-chloro-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4S-(2-chloro-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Acetyl-4S-(2-trifluoromethylbenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Acetyl-4S-(3-chlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Acetyl-4-(3-chlorothiophen-2-carbonylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4S-(2-chlorothiophen-3-carbonylamino)-3,4-dihydro-2,2-dimethyl-2H 1 -benzopyran-3R-ol,
- trans-6-Acetyl-4-(5-bromothiophen-2-carbonylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3,5-dibromobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-chloro-6-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(3-chloro-2-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2,6-dichlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-azido-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-azido-5-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4S-(2-methylbenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Acetyl-4S-(4-methylbenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Acetyl-4-(2-chloro-3-nitrobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-chloro-5-nitrobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4-(2-methoxybenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4S-(3-chloro-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
- trans-6-Acetyl-4-(2-chloro-4-hydroxybenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol,
- trans-6-Acetyl-4S-(2,3-dichlorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol, and
- trans-6-Acetyl-3,4-dihydro-2,2-dimethyl-4-(2-pyrazinecarboxybenzoylamino)-2H-1-benzopyran-3-ol;
- or a pharmaceutically acceptable salt thereof.
- 2. The method according to claim 1 wherein said disorder which is treatable with anti-convulsive agents is epilepsy.
Priority Claims (5)
Number |
Date |
Country |
Kind |
9225881 |
Dec 1992 |
GBX |
|
9225956 |
Dec 1992 |
GBX |
|
9225957 |
Dec 1992 |
GBX |
|
9225963 |
Dec 1992 |
GBX |
|
9225964 |
Dec 1992 |
GBX |
|
Parent Case Info
This appl. is a 371 of PCT/GB93/02512 filed Dec. 8, 1993.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/GB93/02512 |
12/8/1993 |
|
|
7/6/1995 |
7/6/1995 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO94/13656 |
6/23/1994 |
|
|
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5624954 |
Evans et al. |
Apr 1997 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0 126 311 |
Nov 1984 |
EPX |
0 205 292 |
Dec 1986 |
EPX |
0 339 562 |
Nov 1989 |
EPX |